Style | Citing Format |
---|---|
MLA | Rostami SP, et al.. "Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells." Recent Patents on Anti-Cancer Drug Discovery, vol. 19, no. 3, 2024, pp. 342-353. |
APA | Rostami SP, Dehkordi NM, Asgari Y, Bolouri MR, Shayanfar N, Falak R, Kardar GA (2024). Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells. Recent Patents on Anti-Cancer Drug Discovery, 19(3), 342-353. |
Chicago | Rostami SP, Dehkordi NM, Asgari Y, Bolouri MR, Shayanfar N, Falak R, Kardar GA. "Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells." Recent Patents on Anti-Cancer Drug Discovery 19, no. 3 (2024): 342-353. |
Harvard | Rostami SP et al. (2024) 'Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells', Recent Patents on Anti-Cancer Drug Discovery, 19(3), pp. 342-353. |
Vancouver | Rostami SP, Dehkordi NM, Asgari Y, Bolouri MR, Shayanfar N, Falak R, et al.. Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells. Recent Patents on Anti-Cancer Drug Discovery. 2024;19(3):342-353. |
BibTex | @article{ author = {Rostami SP and Dehkordi NM and Asgari Y and Bolouri MR and Shayanfar N and Falak R and Kardar GA}, title = {Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells}, journal = {Recent Patents on Anti-Cancer Drug Discovery}, volume = {19}, number = {3}, pages = {342-353}, year = {2024} } |
RIS | TY - JOUR AU - Rostami SP AU - Dehkordi NM AU - Asgari Y AU - Bolouri MR AU - Shayanfar N AU - Falak R AU - Kardar GA TI - Competitive Effect of Overexpressed C-Terminal of Snail-1 (Csnail) in Control of the Growth and Metastasis of Melanoma Cells JO - Recent Patents on Anti-Cancer Drug Discovery VL - 19 IS - 3 SP - 342 EP - 353 PY - 2024 ER - |